PDF factsheet
      Z

myocardial revascularization in coronary artery disease for diabetic patients , clinical trials results

CABG or PCI versus medical treatment
BARI 2D, 2009
NCT00006305
prompt revascularization with intensive medical therapy
versus
intensive medical therapy alone
patients with type 2 diabetes and heart diseaseopen
Follow-up duration: 5.3 y
US, Canada, Brazil, Mexico, Czech Republic, Austria
CoStar stent versus paclitaxel eluting stent
COSTAR II diabetic (sub group), 2008
CoStar stent (PES)
versus
Taxus stent (PES)
patients with de novo single- or multivessel coronary disease open
Follow-up duration: 8 months
everolimus eluting stent versus sirolimus ES
ESSENCE diabetes,
NCT00997763
everolimus-eluting stent
versus
sirolimus-eluting stent
diabetic patients with angina or documented ischemiaopen
Follow-up duration: 1y for clinical events
South Korea
paclitaxel eluting stent versus bare-metal stent
TAXUS II (diabetics), 2003
TAXUS
versus
NIR stent
Diabetic patients with stable or unstable AP, silent ischaemia; single de novo target lesion with estimatedstenosis >50% and <99%,double-blind
Follow-up duration: 12 months
Europe
TAXUS IV (diabetics), 2005
NCT00292474
TAXUS
versus
EXPRESS
Diabetic patients with stable or unstable AP, provokable ischaemia with a single, previously untreated coronary-artery stenosis (vessel diameter, 2.5 to 3.75 mm; lesion length, 10 to 28 mm)double-blind
Follow-up duration: 9 months
United States
TAXUS V (diabetics), 2005
TAXUS
versus
BMS
Diabetic patients with stable or unstable AP, silent ischaemia with complex or previously unstudied lesions (requiring 2.25-mm, 4.0-mm, and/or multiple stents)double-blind
Follow-up duration: 9 months
United States
TAXUS VI (diabetics), 2005
NCT00297804
TAXUS
versus
Express2 stent
Diabetic patients with stable or unstable AP, silent ischaemia with long, complex coronary artery lesionsdouble-blind
Follow-up duration: 9 months
Europe
paclitaxel eluting stent versus sirolimus eluting stent
ISAR-test (diabetics), 2006
Taxus
versus
rapamycin stent
diabetics patients with de novo lesions in native coronary vessels, excluding the left main trunkopen
Follow-up duration: 9 months
germany
PCI with drug-eluting stents versus CABG
SYNTAX (diabetic), 2010
NCT00114972
paclitaxel-eluting stents
versus
surgical revascularization
sub group of diabetic patients with left main and/or 3-vessel disease
Follow-up duration: 1 year
FREEDOM, 2012
NCT00086450
percutaneous coronary stenting
versus
CABG
patients with diabetes and multivessel coronary artery diseaseopen
Follow-up duration: 3.8 yrs (median)
international
sirolimus eluting stent versus bare-metal stent
DECODE, 2005
NCT00489164
CYPHER (Up to 3 stents per patient were allowed)
versus
Bx VELOCITY (Up to 3 stents per patient were allowed)
Stable or unstable angina in diabetic patients with with up to 2 de novo lesions in up to 2 native coronary vesselsopen
Follow-up duration: 1 year
US, Asia/Pacific
DIABETES, 2005
Cypher
versus
Bx Velocity/Sonic
de novo lesions in native coronary arteriesin 1, 2, or 3 native vessels with symptoms or objective evidence of ischemia; vessel size smaller than 4.0 mmopen
Follow-up duration: 9 months
Spanish
Ravel (diabetics), 2004
coated Bx velocity
versus
Bx VELOCITY
sub groups of diabetic patients with de novo native coronary arterylesions 2.5 to 3.5 mm in diameter by visualassessment that could be covered by an 18-mm stentNA
Follow-up duration: 6 months
Europe
SES-SMARt (diabetics), 2005
Cypher
versus
Bx Sonic
Diabetic patients with de novo target lesion <=2.75 mm in diameter in a native coronary artery that could be completely covered by a single stent (maximum length 33 mm) single-blind
Follow-up duration: 8 months
Italy
SIRIUS (diabetics), 2003
SES
versus
BMS
sub group of diabetics patients of SIRIUS studydouble-blind
Follow-up duration: 12 months
US
sirolimus eluting stent versus paclitaxel eluting stent
DES-DIABETES, 2008
sirolimus-eluting stent
versus
paclitaxel-elutingstent
diabetic patients with angina pectoris and/or a positive stress test and a native coronary lesionopen
Follow-up duration: 9 months (1 year)
Korea
ISAR-DIABETES, 2005
Taxus
versus
Cypher
Diabetic patients. AP or positive stress, no AMI with clinically significant angiographic stenosis in a native coronary vesselĀ­open
Follow-up duration: 9 months
Germany
REALITY (diabetics), 2006
SES
versus
PES
open
Follow-up duration: 12 months
worldwide
SIRTAX diabetics, 2005
NCT00297661
Cypher
versus
Taxus
Sub groups of diabetics patients with either stable angina or an acute coronary syndrome single-blind
Follow-up duration: 12 months
Switzerland
TAxi (diabetics), 3000
SES
versus
PES
open
Follow-up duration: 12 months
Switzerland
Tomai, 2008
sirolimus-eluting stent
versus
paclitaxel-eluting stent
diabetic patient with multiple de novo coronary artery lesionsNA
Follow-up duration: 8 months
Italy
stent versus CABG
CARDia (PCI), 2008
ISRCTN19872154
PCI plus stenting (and routine abciximab)
versus
CABG
Patients with diabetes and symptomatic multivessel coronary artery disease or complex single-vessel disease. open
Follow-up duration: 1 y
UK, Ireland

  Options


in first

in second

  Filter